Vincentelli J, Luccioni A, Devictor B, Dussol B, Lechevallier E, Bertault-Peres P, Coulange C, Berland Y, Penot Ragon C
Department of Pharmacy, Department of Renal Transplantation, CHU-Sud, Public Health Service, Université de la Méditerranée, Marseille, France.
J Clin Pharm Ther. 2003 Aug;28(4):273-7. doi: 10.1046/j.1365-2710.2003.00489.x.
To determine whether Belzer solution (Viaspan, Bristol-Myers Squibb, Brussels, Belgium), which is more expensive than Eurocollins solution, was better at preventing delayed graft function (DGF) and whether it was cost-effective as it could potentially reduce post-transplantation complications.
The risk of occurrence of complications associated with the use of these two rinsing and preserving solutions was estimated from a survey of 106 patients undergoing renal transplantation between 1 January 1993 and 31 March 1998. Both efficacy and adverse outcomes were recorded along with the costs directly associated with the transplantation procedure in the hospital setting: hospitalization, rinsing and preserving solutions, medical and technical interventions and diagnostic tests.
For the 45 kidney grafts rinsed and preserved with Eurocollins (strategy S1: n1 = 45) the cost/graft was estimated at 40 euros. With Viaspan (strategy S2: n2 = 61) the corresponding cost/graft was 424 euros. Logistic regression analysis showed that Viaspan was better than Eurocollins solution (ebeta = 0.437; P = 0.05) in preventing DGF. Overall, S2 was less expensive than S1, from the hospital's perspective. The mean difference per patient was 278 euros, which amounts to a saving of 2% of the total cost per renal transplantation. For rinsing and preserving kidney grafts Belzer solution is therefore preferable to Eurocollins solution.
确定比欧科林溶液更昂贵的贝尔泽溶液(维司配能,百时美施贵宝公司,比利时布鲁塞尔)在预防移植肾功能延迟恢复(DGF)方面是否更优,以及其是否具有成本效益,因为它可能会减少移植后并发症。
通过对1993年1月1日至1998年3月31日期间接受肾移植的106例患者进行调查,评估使用这两种冲洗和保存溶液相关并发症的发生风险。记录疗效和不良结局以及与医院环境中移植手术直接相关的费用:住院、冲洗和保存溶液、医疗和技术干预以及诊断检查。
对于45个用欧科林溶液冲洗和保存的肾移植(策略S1:n1 = 45),每个移植的成本估计为40欧元。使用维司配能(策略S2:n2 = 61)时,每个移植的相应成本为424欧元。逻辑回归分析表明,在预防DGF方面,维司配能优于欧科林溶液(ebeta = 0.437;P = 0.05)。总体而言,从医院角度看,S2比S1成本更低。每位患者的平均差异为278欧元,相当于每次肾移植总成本节省2%。因此,对于冲洗和保存肾移植,贝尔泽溶液优于欧科林溶液。